Spiro[bicyclo[2.2.1]heptane-7,1'-cyclopropane]-5-ene-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Spiro[bicyclo[2.2.1]heptane-7,1'-cyclopropane]-5-ene-2-carboxylic acid
• 英文别名: spiro[bicyclo[2.2.1]hept-5-ene-7,1'-cyclopropane]-2-carboxylic acid
• 化学式: C₁₀H₁₂O₂
• 分子量: 164.2
• InChiKey: GUQRBBFSKQZSRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-trifluoromethyl-2-chloroethylsulfenyl chloride 、 Spiro[bicyclo[2.2.1]heptane-7,1'-cyclopropane]-5-ene-2-carboxylic acid 以87%的产率得到
  参考文献：
  名称：

  SIZOV, A. YU.;LINEV, V. V.;KONDRASHOV, N. V.;KOLOMIETS, A. F.;FOKIN, A. V+, IZV. AN CCCP. CEP. XIM.,(1990) N, S. 150-155

  摘要：

  DOI：

文献信息

• Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
  申请人：Allergan, Inc.

  公开号：US10208071B2

  公开（公告）日：2019-02-19

  The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.

  本发明涉及一种在需要治疗的受试者中治疗眼部炎症疾病的方法，该方法包括施用一种药物组合物，该药物组合物包含治疗有效量的至少一种甲酰肽受体 2 的激动剂。
• Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
  申请人：Allergan, Inc.

  公开号：US10434112B2

  公开（公告）日：2019-10-08

  The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).

  本发明涉及一种通过局部或全身给药治疗需要此类治疗的受试者的皮肤炎症和皮肤疾病的方法，该方法包括给药一种药物组合物，该药物组合物包含治疗有效量的至少一种甲酰肽受体 2（FPR2）激动剂。
• USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES
  申请人：Allergan, Inc.

  公开号：US20170216326A1

  公开（公告）日：2017-08-03

  The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
• USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES
  申请人：Allergan, Inc.

  公开号：US20170320897A1

  公开（公告）日：2017-11-09

  The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.